

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Luo et al.

Group Art Unit: 1645

Serial No. 09/041,236

Examiner: Lee, L.

Filed: Mar 11, 1998

Attorney Docket No. EX98-001

For: *Semaphorin K1*

## CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted by fax to  
(703)308-4426 on August 29, 2000

Signed

Richard Osman

AMENDMENTThe Assistant Commissioner for Patents  
Washington, DC 20231

Dear Commissioner:

- 1 10. (Twice Amended) An isolated polypeptide comprising a sequence selected from the group consisting of:
- (a) at least 100 contiguous residues of SEQ ID NO:2,
  - (b) at least 60 contiguous residues of residues 340-634 of SEQ ID NO:2, and
  - (c) at least 12 contiguous residues of residues 481-634 of SEQ ID NO:2,
- wherein the polypeptide has a functionality selected from the group consisting of enhancing organotypic neurite outgrowth from damaged neurons undergoing nerve fiber atrophy and eliciting a SemaK1-specific antibody.

## REMARKS

Support for the use of the claimed polypeptides are used in therapeutic applications to enhance organotypic neurite outgrowth from damaged neurons undergoing nerve fiber atrophy is found on p.18, lines 6-16). Support for the use of the claimed polypeptides to elicit SemaK1-specific antibodies is found on p.5, line 19 - p.6, line 31; such antibodies provide both diagnostic (p.7, lines 13-19) and therapeutic (p.18, lines 16-29) applications.

Respectfully submitted,  
SCIENCE & TECHNOLOGY LAW GROUPRichard Aron Osman, Ph.D., Reg. No. 36,627  
Tel: (650) 343-4341; Fax: (650) 343-4342OK TO ENTER  
OK TO ENTER  
LL 9/11/00

35